Previous close | 0.5750 |
Open | 0.5650 |
Bid | 0.5650 x N/A |
Ask | 0.5950 x N/A |
Day's range | 0.5650 - 0.5650 |
52-week range | 0.4480 - 1.5700 |
Volume | |
Avg. volume | 16 |
Market cap | 546.255M |
Beta (5Y monthly) | 0.36 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 28 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (JSKN016-101) of JSKN016, a novel bispecific antibody-drug conjugate (ADC) targeting HER3 and TROP2, in the treatment of Chinese patients with advanced malignant solid tumors.
Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted in China (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, will be presented for the first time at the 2024 Annual Meeting of American Society of Clinical Oncology (2024 ASCO Annual Meeting) from May 31 to June 4, 2024, in Chicago, IL, U.S..
Alphamab Oncology (stock code: 9966.HK) announced the data from phase I clinical study conducted in Australia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, were presented as a poster at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024).